298 related articles for article (PubMed ID: 20495085)
21. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
Mundhofir FE; Wulandari CE; Prajoko YW; Winarni TI
Asian Pac J Cancer Prev; 2016; 17(3):1539-46. PubMed ID: 27039803
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
[No Abstract] [Full Text] [Related]
23. Breast and ovarian cancer genetics and prevention.
Altaha R; Reed E; Abraham J
W V Med J; 2003; 99(5):187-91. PubMed ID: 14959510
[TBL] [Abstract][Full Text] [Related]
24. [Genetics and cancer of the breast].
Sobol H; Bignon YJ; Eisinger F; Birnbaum D; Fervers B
Ann Chir; 1994; 48(4):303-8. PubMed ID: 8085754
[TBL] [Abstract][Full Text] [Related]
25. Variability in Cancer Risk with BRCA Mutations.
Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
[No Abstract] [Full Text] [Related]
26. Genetic/familial high-risk assessment: breast and ovarian.
Daly MB; Axilbund JE; Bryant E; Buys S; Eng C; Friedman S; Esserman LJ; Farrell CD; Ford JM; Garber JE; Jeter JM; Kohlmann W; Lynch PM; Marcom PK; Nabell LM; Offit K; Osarogiagbon RU; Pasche B; Reiser G; Sutphen R; Weitzel JN;
J Natl Compr Canc Netw; 2006 Feb; 4(2):156-76. PubMed ID: 16451772
[No Abstract] [Full Text] [Related]
27. Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
Rhiem K; Bücker-Nott HJ; Hellmich M; Fischer H; Ataseven B; Dittmer-Grabowski C; Latos K; Pelzer V; Seifert M; Schmidt A; Rezek D; Groh U; Meinerz W; Crommelinck D; Hahnen E; Wesselmann S; Schmutzler RK
Breast J; 2019 May; 25(3):455-460. PubMed ID: 30953388
[TBL] [Abstract][Full Text] [Related]
28. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
29. [Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer].
Rumiantseva UV; Rumiantsev PO; Kiseleva MV
Vopr Onkol; 2008; 54(3):251-9. PubMed ID: 18652227
[No Abstract] [Full Text] [Related]
30. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Lynch HT; Silva E; Snyder C; Lynch JF
Breast J; 2008; 14(1):3-13. PubMed ID: 18086272
[TBL] [Abstract][Full Text] [Related]
31. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
[TBL] [Abstract][Full Text] [Related]
32. Treating the genetic make-up of breast cancer: a new fashion?
Linn SC; Jonkers J
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1065-7. PubMed ID: 17725409
[No Abstract] [Full Text] [Related]
33. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
Høberg-Vetti H; Eide GE; Siglen E; Listøl W; Haavind MT; Hoogerbrugge N; Bjorvatn C
Acta Oncol; 2019 Feb; 58(2):175-181. PubMed ID: 30334464
[TBL] [Abstract][Full Text] [Related]
34. Impact of Implementing B-RST
Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
[TBL] [Abstract][Full Text] [Related]
35. Unknown significance.
Couzin-Frankel J
Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
[No Abstract] [Full Text] [Related]
36. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
37. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
Ramus SJ; Harrington PA; Pye C; DiCioccio RA; Cox MJ; Garlinghouse-Jones K; Oakley-Girvan I; Jacobs IJ; Hardy RM; Whittemore AS; Ponder BA; Piver MS; Pharoah PD; Gayther SA
Hum Mutat; 2007 Dec; 28(12):1207-15. PubMed ID: 17688236
[TBL] [Abstract][Full Text] [Related]
38. Mother still knows best: cancer-related gene mutations, familial privacy, and a physician's duty to warn.
Brownrigg A
Fordham Urban Law J; 1999 Jan; 26(2):247-79. PubMed ID: 16437785
[No Abstract] [Full Text] [Related]
39. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
40. Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
Pasini B; Pierotti MA
Dis Markers; 1999 Oct; 15(1-3):41-3. PubMed ID: 10595250
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
